Literature DB >> 27100028

Tumor histopathology predicts outcomes after resection of colorectal cancer liver metastases treated with and without pre-operative chemotherapy.

Srinevas K Reddy1, Robin J Parker1, Joseph W Leach1, Mark J Hill1, Lawrence J Burgart1.   

Abstract

BACKGROUND AND OBJECTIVES: Study objectives, included determination of: (i) associations between radiologic and pathologic responses of colorectal cancer liver metastases (CRCLM) to chemotherapy; and (ii) whether CRCLM histopathology is associated with recurrence free survival (RFS) after resection among patients not treated with pre-operative chemotherapy (untreated).
METHODS: Demographics, clinicopathologic characteristics, and outcomes among patients who underwent CRCLM resection from 2007 to 2014 were reviewed. Tumor regression grade (TRG) of 1-2 and 4-5 depict low and high proportions of viable tumor relative to fibrosis, respectively.
RESULTS: Of 138 patients, 84 (60.9%) were treated with pre-operative chemotherapy. In these patients, there was no difference in proportions with TRG 1-2 among those with verses without radiologic response (26.9% vs. 18.8%, P = 0.393). TRG 1-2 was associated with superior RFS on univariable (median 15 vs. 6 months, P < 0.001) and multivariable (P = 0.005) analyses. Radiologic response was not associated with RFS. Among untreated patients (n = 54), TRG 4-5 was associated with poor RFS on univariable (median 44 vs. 15 months, P = 0.011) and multivariable (P = 0.012) analyses.
CONCLUSIONS: High proportions of CRCLM fibrosis occur in 20% of patients without radiologic response to chemotherapy. Among untreated patients, high proportion of viable tumor relative to fibrosis is associated with poor RFS after resection. J. Surg. Oncol. 2016;113:456-462.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  liver resection; recurrence free survival; tumor regression grade

Mesh:

Year:  2016        PMID: 27100028     DOI: 10.1002/jso.24144

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Late gadolinium MRI enhancement of colorectal liver metastases is associated with overall survival among nonsurgical patients.

Authors:  Helen M C Cheung; Jin K Kim; John Hudson; Natalie Coburn; Paul J Karanicolas; Calvin Law; Laurent Milot
Journal:  Eur Radiol       Date:  2019-04-01       Impact factor: 5.315

2.  Delayed MRI Enhancement of Colorectal Cancer Liver Metastases Is Associated With Metastatic Mutational Profile.

Authors:  Arun Seth; Yutaka Amemiya; Helen Cheung; Eugene Hsieh; Calvin Law; Laurent Milot
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

3.  Histological tumor response assessment in colorectal liver metastases after neoadjuvant chemotherapy: impact of the variation in tumor regression grading and peritumoral lymphocytic infiltration.

Authors:  Yibo Cai; Xingang Lu; Xiu Zhu; Haixing Ju; Wenyong Sun; Wei Wu
Journal:  J Cancer       Date:  2019-10-06       Impact factor: 4.207

4.  The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator.

Authors:  Yanbo Xu; Jiarui He; Weihao Li; Weili Zhang; Songran Liu; Jiahua He; Zhizhong Pan; Zhenhai Lu; Jianhong Peng; Junzhong Lin
Journal:  Pathol Oncol Res       Date:  2022-09-06       Impact factor: 2.874

5.  Late gadolinium enhancement of colorectal liver metastases post-chemotherapy is associated with tumour fibrosis and overall survival post-hepatectomy.

Authors:  Helen M C Cheung; Paul J Karanicolas; Eugene Hsieh; Natalie Coburn; Tishan Maraj; Jin K Kim; Howaida Elhakim; Masoom A Haider; Calvin Law; Laurent Milot
Journal:  Eur Radiol       Date:  2018-02-23       Impact factor: 5.315

6.  LncRNA CRNDE and lncRNA SNHG7 are Promising Biomarkers for Prognosis in Synchronous Colorectal Liver Metastasis Following Hepatectomy.

Authors:  Peixian Zhang; Lan Shi; Linjing Song; Yi Long; Kehua Yuan; Wanbao Ding; Lei Deng
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.